Titolo della ricerca: efficacy and safety of MIDOSTAURIN IN NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA PATIENTS.
Progetto di ricerca: ACUTE MYELOID LEUKEMIA (AML) IS THE MOST COMMON ACUTE LEUKEMIA IN ADULTS: THE PROGNOSIS IS HIGHLY DEPENDENT UPON CLINICAL AND MOLECULAR CHARACTERISTICS, WITH COMPLETE RESPONSE (CR) RATE RANGING FROM 50% TO 80% DEPENDING UPON BASELINE PATIENTCHARACTERISTICS. ONE OF THE MOST COMMON MUTATIONS (25-30%OF PATIENTS) DETECTED IN AML OCCURS IN THE GENE ENCODING FMS-LIKE TYROSINE KINASE 3 (FLT3), A TYPE III RECEPTOR TYROSINE KINASE WHICH REGULATES NORMAL GROWTH AND DIFFERENTIATION OF CD34+ HEMATOPOIETIC CELLS VIA SIGNALING THROUGH MULTIPLE PATHWAYS INCLUDING PI3 KINASE-AKT, MAPK, AND STAT5a. MIDOSTAURIN IS AN ORALLY ADMINISTERED TYPE III TYROSINE KINASE INHIBITOR THAT SPECIFICALLY TARGETS FLT3 AND HAS BEEN SHOWN TO SIGNIFICANTLY IMPROVE SURVIVAL IN YOUNGER PATIENTS WITH FLT3-MUT AML WHEN GIVEN IN COMBINATION WITH STANDARD CYTOTOXIC CHEMOTHERAPY. AIM OF THIS PROJECT IS TO PROSPECTIVELY INSERT DATA INTO THE CLINIC-SCIENTIFIC DATABASE AND TO CHECK THE ACCURACY OF DATA IN ACCORDANCE TO THE EXPERIMENTAL STANDARD PROCEDURES.